Combo stops late-stage TNBC in mice

Researchers in Australia have successfully tested a drug combination to fight late-stage triple-negative breast cancer in mice—with a 100 percent success rate.  The treatment trial—at Queensland Institute of Medical Research— demonstrates that targeting radiation to an overload of proteins (known as EGFR) together with a dramatically reduced dose of chemotherapy is effective in stopping both the cancer growth and its recurrence. 

 “It’s when breast cancer reoccurs, or spreads, that most fatalities are reported,” Professor Kum Khanna, from QIMR’s Signal Transduction Laboratory. “This is early stage research, and there’s a long way to go, but it’s the first time we’ve seen a therapy that stops the recurrence and treats the spread of these triple-negative breast cancers.” . 

Researchers hope that the process can successful go through stage 1, 2, and 3 clinical trials within ten years.

Ten years!!!!!!!!!  Hurry, folks.  We're waiting.

Read the news release here.

Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.

Please consider a donation to Positives About Negative to keep this site going.  This work is entirely supported by readers.  Just click on the Donate button in the right of the page.  Thank you!